FDA approvals & clinical catalysts

Definition

FDA decisions and clinical-trial readouts are biotech’s scheduled binary events: a PDUFA date (the FDA’s target action date on a drug application) or a Phase 2/3 data readout can move a single-asset company 50-80% in either direction overnight. They are the purest event-catalyst structures in equities — dated (mostly), binary (mostly), with per-stage base rates published — and the KB’s standing example of positions that must be sized as binaries, not as stocks.

How it works / structure

• The catalyst calendar (engine-executable): PDUFA dates (disclosed by companies; the FDA acts on or before — early actions and delays both occur), advisory-committee (AdComm) meetings (public, scheduled, vote outcomes precede decisions), and trial readouts (guided to quarters, not dates — “H2 data” is a window, not a timestamp).
• The base rates (labeled industry data): the BIO/QLS compilation puts overall Phase-1-to-approval likelihood near 8%, Phase 3 success near 50-60%, and approval-after- filing high — per-stage, per-indication rates vary widely; the platform uses them as priors, labeled as industry (not peer-reviewed) statistics.
• The pricing structure: options straddles price the binary (opt-expected-move at event tenor); IV runs extreme into readouts and crushes after (strategy-straddle economics at their sharpest); the stock’s move frequently exceeds OR badly underperforms the priced move — both documented shapes.
• Sizing doctrine: single-asset biotechs can gap −70% on failure (no bid between prices); risk-fixed-fractional arithmetic applies to the GAP severity, not the ATR; defined-risk options structures cap the tail the stock cannot.

When it applies

Any position in a development-stage biotech (the calendar check is mandatory — holding through a readout is an event thesis whether intended or not, fa-sector-biotech); event- vol structures around dated catalysts; post-event drift observation (approval-to-launch repricing is a slower, separate thesis).

Risk profile & failure modes

• Binary sizing failure: position sizes calibrated to daily vol meet 60% gaps — the sector’s signature account destroyer; scenario-severity sizing is structural.
• Date drift: PDUFA extensions and readout-window slippage strand event positions in theta bleed (mgmt-time-based-exit boundaries need window, not date, logic).
• AdComm head-fakes: advisory votes are advisory — the FDA usually but not always follows; the gap between vote and decision is its own event.
• Information asymmetry: trial-design literacy (endpoints, powering, interim analyses) separates informed priors from coin flips; the platform treats unmodeled readouts as unpriceable, not as 50/50.

Evidence & limits

The regulatory process is FDA-documented; success-rate base rates are industry compilations (labeled, not peer-reviewed); event-move magnitudes are observable in price history. No edge is claimed in predicting outcomes — the KB’s contribution is calendar discipline, base-rate priors, and binary sizing doctrine.

Falsifiable-thesis examples

Illustrations only, not signals:

• “X will receive FDA approval by its PDUFA date (binary thesis, sized to the failure gap)” — falsified by a CRL or extension.
• “X’s realized move at readout will exceed the straddle- priced move (underpriced-binary thesis)” — falsified by the realized-vs-priced comparison.

Cross-references

• The sector frame: fa-sector-biotech
• The pricing machinery: opt-expected-move, strategy-straddle, opt-implied-volatility
• The sizing doctrine: risk-fixed-fractional, risk-scenario-analysis
• The discipline source: lens-event-catalyst